7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZ0[1,2-A]PYRID0[3,4-E] PYRIMIDIN-5 (1 H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY
This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.
1 .- 119 . (canceled)
120 . A method of identifying whether a subject having cancer is likely to be responsive to administration of a compound:
or a pharmaceutically acceptable salt thereof,
comprising:
(i) obtaining a biological sample from the subject;
(ii) measuring expression, post-translational modifications, or activity levels of or mutations in at least one dopamine receptor in the sample;
(iii) comparing the levels measured and/or the mutations found in the sample to those for a pre-determined standard; and
(iv) determining whether the subject is likely to be responsive to administration of compound (1), based on the levels measured and/or mutations found in the sample to those for the pre-determined standard.
121 . The method of claim 120 , wherein the dopamine receptor is selected from DRD2, DRD2S, DRD2L, and DRD3.
122 . The method of claim 120 , wherein the dopamine receptor is from the D2-like family of dopamine receptors.
123 . The method of claim 120 , further comprising the step of administering an effective amount of the compound to the subject.
124 . A method of assessing the effectiveness of or monitoring a subject having cancer and undergoing administration of a compound:
or a pharmaceutically acceptable salt thereof,
comprising:
(i) obtaining a biological sample from the subject;
(ii) measuring expression, post-translational modifications, or activity levels of or mutations in at least one dopamine receptor in the sample;
(iii) comparing the levels measured and/or the mutations found in the sample to those for a pre-determined standard; and
(iv) determining whether the subject is responsive to administration of compound (1), based on the levels measured and/or mutations found in the sample to those for the pre-determined standard.
125 . The method of claim 124 , wherein the dopamine receptor is selected from DRD2, DRD2S, DRD2L, and DRD3.
126 . The method of claim 124 , wherein the dopamine receptor is from the D2-like family of dopamine receptors.
127 . (canceled)
128 . A method for screening a potential cancer therapeutic, comprising:
(i) contacting at least one dopamine receptor with a test compound suspected of being a cancer therapeutic;
(ii) measuring the binding affinity or interaction of the test compound to the at least one dopamine receptor; and
(iii) comparing the binding affinity or interaction of the test compound to a pre-determined threshold, wherein inhibition of the at least one dopamine receptor by the test compound comparable to or greater than the threshold is indicative of a cancer therapeutic.
129 . The method of claim 128 , wherein the dopamine receptor is selected from DRD2, DRD2S, DRD2L, and DRD3.
130 . The method of claim 128 , wherein inhibition of the D2-like family of dopamine receptors is indicative of a cancer therapeutic.
131 . The method of claim 128 , wherein inhibition of both DRD2 and DRD3 dopamine receptors is indicative of a cancer therapeutic.
132 . The method according to any one of claims 128-131 , wherein the pre-determined threshold is the inhibition of the at least one dopamine receptor by a compound:
or a pharmaceutically acceptable salt thereof,
133 .- 141 . (canceled)